Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore

Gilberto Lopes, Thomas Burke, James Pellissier, Xu Hao Zhang, Seema Dedhiya, Alexandre Chan

Research output: Contribution to journalArticle

Abstract

Background: Aprepitant (a neurokinin 1 receptor antagonist), in combination with a serotonin receptor antagonist (5-HT3 RA) and dexamethasone, has demonstrated superior efficacy on end points related to chemotherapy-induced nausea and vomiting (CINV) compared with standard care (combination 5-HT3 RA and dexamethasone).Objective: To determine the cost-effectiveness of an aprepitant-containing regimen compared with current clinical practice for the prevention of CINV in patients receiving highly emetogenic chemotherapy (HEC) in Singapore. Methods: A decision-analytic model was constructed to assess the costs and outcomes associated with an aprepitant-containing regimen compared with standard care in the prevention of CINV following HEC. Three scenarios were modeled on the basis of results of four double-blind randomized clinical trials of aprepitant. CINV event probabilities were calculated on the basis of the occurrence of nausea and vomiting and the need for rescue medication in the 5 days following a single cycle of HEC. The analysis was conducted from the Singapore health care system perspective. Results: Aprepitant reduced emesis and nausea, resulting in small but clinically important improvements when measured in quality-adjusted life-years. The aprepitant-containing regimen was associated with higher acquisition costs but lower costs relating to patient management, hospitalization, and use of rescue medication. Across the scenarios, the incremental cost per emetic event avoided ranged from cost saving to Singapore $63 (US $51). The incremental cost-effectiveness ratio ranged from cost saving to Singapore $49,800 per quality-adjusted life-year gained (US $40,600). The analysis was relatively insensitive to changes in the inputs. Conclusions: Aprepitant is a clinically important and cost-effective therapy for the prevention of CINV in patients treated with HEC in Singapore.

Original languageEnglish (US)
Pages (from-to)66-74
Number of pages9
JournalValue in Health Regional Issues
Volume1
Issue number1
DOIs
StatePublished - 2012

    Fingerprint

Keywords

  • Aprepitant
  • Chemotherapy
  • Cost-effectiveness
  • Emesis
  • Singapore

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Economics, Econometrics and Finance (miscellaneous)

Cite this